You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Led by DNAstack and supported by Canada's Digital Technology Supercluster, COVID Cloud looks to build a nationwide bioinformatics infrastructure to address the pandemic.
Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.
Researchers identified variants in the germline that appear to influence DNA methylation levels in prostate cancer tumors or in precancerous tissues.
Researchers used exome capture RNA sequencing to come up with a collection of circRNAs in dozens of cancer types, including proposed prostate cancer markers.
In Genome Research this week: transcriptomic profiles of centenarians, role for PRDM9 expression in various tumor types, and more.
In Genome Biology this week: genome sequencing study of a wild cherry tree, transcriptomic analysis of a planarian model organism, and more.
Researchers found that air pollution levels affected the expression of genes linked to cardio-metabolic and respiratory traits more than genetic ancestry.
Expression and copy number profiles from histologically normal duct tissue near tumors suggest a "field of cancerization" may exist in epithelial cells around cancer.
In Nucleic Acids Research this week: disease network resource, database of epigenetic consequences of de novo mutations, and more.
Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.